Novo Nordisk partners with Anthropic to accelerate drug discovery

Anthropic AI: Anthropic is an AI company known for its Claude family of frontier models designed for safe and capable reasoning in complex domains. It is collaborating with Novo Nordisk to apply Claude and Claude Science tools to scientific problems in drug discovery, biological reasoning, and AI-driven software engineering. The partnership emphasizes shortening research timelines while maintaining robust data governance and human oversight. Novo Nordisk: Novo Nordisk is a Danish pharmaceutical company focused on developing treatments for chronic diseases, particularly diabetes and obesity. It has recently rebranded elements of its operations under the shorter name Novo while pursuing an ambition to become the world’s most AI-driven healthcare company. The firm is partnering with Anthropic to integrate frontier AI models into its R&D workflows for accelerating drug discovery and development. AI Adoption: Novo Nordisk is expanding its use of advanced AI models across R&D to increase productivity and compress development timelines for new medicines targeting chronic diseases. Scientific Opportunity: AI tools are enabling completely new scientific opportunities by aiding reasoning and deeper understanding of human biology and drug mechanisms of action.